About erasca inc - ERAS
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
ERAS At a Glance
Erasca, Inc.
3115 Merryfield Row
San Diego, California 92121
| Phone | 1-858-465-6511 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -124,546,000.00 | |
| Sector | Health Technology | Employees | 103 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ERAS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.251 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.437 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.057 |
ERAS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,209,184.466 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ERAS Liquidity
| Current Ratio | 10.04 |
| Quick Ratio | 10.04 |
| Cash Ratio | 9.683 |
ERAS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -27.373 |
| Return on Equity | -33.271 |
| Return on Total Capital | -33.452 |
| Return on Invested Capital | -29.724 |
ERAS Capital Structure
| Total Debt to Total Equity | 14.497 |
| Total Debt to Total Capital | 12.661 |
| Total Debt to Total Assets | 11.569 |
| Long-Term Debt to Equity | 12.939 |
| Long-Term Debt to Total Capital | 11.301 |